Evidence map›Paper›PMID 29614433›Full record

ReviewCurrent opinion in pharmacology2018

Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities.

Maurizio Pacifici

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. KIF26B Silencing Prevents Osseous Transdifferentiation of Progenitor/Stem Cells and Attenuates Ectopic Calcification in a Murine Model.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  8. Review
  9. Article
  10. Review
  11. Progressive osseous heteroplasia: a case report and literature review.American journal of translational research · 2021
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Maurizio PacificiTranslational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Electronic address: Pacificim@email.chop.edu.
Children's Hospital of Philadelphia · US

Funding

Mechanisms regulating normal and ectopic endochondral ossificationR01AR071946 · NIAMS · CHILDREN'S HOSP OF PHILADELPHIA · PI PACIFICI, MAURIZIO · 2017 to 2021
$1.8M
NIAMS NIH HHS R01 AR071946
6 · The paper itself

Abstract

Heterotopic ossification (HO) involves the formation and accumulation of extraskeletal bone tissue at the expense of local tissues including muscles and connective tissues. There are common forms of HO that are triggered by extensive trauma, burns and other bodily insults, and there are also rare congenital severe forms of HO that occur in children with Fibrodysplasia Ossificans Progressiva or Progressive Osseous Heteroplasia. Given that HO is often preceded by inflammation, current treatments usually involve anti-inflammatory drugs alone or in combination with local irradiation, but are not very effective. Recent studies have provided novel insights into the pathogenesis of acquired and genetic forms of HO and have used the information to conceive and test new and more specific therapies in animal models. In this review, I provide salient examples of these exciting and promising advances that are undoubtedly paving the way toward resolution of this debilitating and at times fatal disease.

Indexed as

AnimalsAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalBone and BonesBone Diseases, MetabolicDrug DiscoveryGenetic Predisposition to DiseaseHumansMolecular Targeted TherapyMyositis OssificansOssification, HeterotopicOsteogenesisPhenotypeSkin Diseases, GeneticAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID29614433
PMCPMC6015534
OpenAlexW2795168968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.